Northern Trust’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$728M Sell
941,941
-2,992
-0.3% -$2.29M 0.1% 192
2025
Q4
$729M Sell
944,933
-39,859
-4% -$27.1M 0.09% 188
2025
Q3
$554M Buy
984,792
+26,223
+3% +$14.8M 0.07% 235
2025
Q2
$503M Sell
958,569
-43,181
-4% -$24.1M 0.07% 245
2025
Q1
$635M Sell
1,001,750
-53,079
-5% -$36.5M 0.09% 197
2024
Q4
$751M Buy
1,054,829
+136,184
+15% +$114M 0.11% 172
2024
Q3
$966M Sell
918,645
-48,081
-5% -$53.5M 0.16% 121
2024
Q2
$1.02B Sell
966,726
-24,739
-2% -$24M 0.17% 108
2024
Q1
$954M Sell
991,465
-54,943
-5% -$52.2M 0.16% 121
2023
Q4
$919M Sell
1,046,408
-20,802
-2% -$17.1M 0.17% 121
2023
Q3
$878M Buy
1,067,210
+34,326
+3% +$27M 0.17% 115
2023
Q2
$742M Sell
1,032,884
-121,689
-11% -$93.8M 0.14% 133
2023
Q1
$949M Sell
1,154,573
-9,439
-0.8% -$7.12M 0.19% 104
2022
Q4
$840M Sell
1,164,012
-24,785
-2% -$18.3M 0.18% 113
2022
Q3
$819M Sell
1,188,797
-10,365
-0.9% -$6.52M 0.19% 106
2022
Q2
$709M Sell
1,199,162
-1,952
-0.2% -$1.27M 0.15% 129
2022
Q1
$839M Sell
1,201,114
-2,212
-0.2% -$1.4M 0.15% 129
2021
Q4
$760M Buy
1,203,326
+3,291
+0.3% +$2.02M 0.12% 149
2021
Q3
$726M Buy
1,200,035
+38,532
+3% +$23.9M 0.13% 141
2021
Q2
$649M Sell
1,161,503
-15,589
-1% -$7.9M 0.11% 157
2021
Q1
$557M Sell
1,177,092
-65,883
-5% -$32.1M 0.1% 176
2020
Q4
$600M Sell
1,242,975
-43,727
-3% -$23.6M 0.12% 158
2020
Q3
$720M Buy
1,286,702
+61,531
+5% +$37.3M 0.16% 120
2020
Q2
$764M Buy
1,225,171
+264,126
+27% +$150M 0.18% 103
2020
Q1
$469M Buy
961,045
+14,449
+2% +$5.96M 0.13% 147
2019
Q4
$355M Buy
946,596
+4,771
+0.5% +$1.61M 0.08% 240
2019
Q3
$261M Sell
941,825
-36,693
-4% -$10.9M 0.06% 294
2019
Q2
$306M Buy
978,518
+5,530
+0.6% +$1.84M 0.07% 258
2019
Q1
$400M Buy
972,988
+20,218
+2% +$8.33M 0.1% 202
2018
Q4
$356M Buy
952,770
+22,468
+2% +$8.22M 0.1% 196
2018
Q3
$376M Sell
930,302
-3,943
-0.4% -$1.5M 0.09% 212
2018
Q2
$322M Buy
934,245
+17,931
+2% +$5.61M 0.08% 234
2018
Q1
$316M Sell
916,314
-18,895
-2% -$6.57M 0.08% 245
2017
Q4
$352M Sell
935,209
-22,751
-2% -$9.21M 0.09% 226
2017
Q3
$428M Buy
957,960
+26,677
+3% +$12.7M 0.11% 184
2017
Q2
$457M Buy
931,283
+6,977
+0.8% +$3.05M 0.13% 156
2017
Q1
$358M Buy
924,306
+29,484
+3% +$10.9M 0.1% 193
2016
Q4
$328M Sell
894,822
-28,866
-3% -$11M 0.1% 199
2016
Q3
$371M Buy
923,688
+157
+0% +$63K 0.12% 177
2016
Q2
$323M Sell
923,531
-105
-0% -$40.4K 0.1% 196
2016
Q1
$338M Sell
923,636
-3,248
-0.4% -$1.34M 0.11% 182
2015
Q4
$503M Sell
926,884
-37,488
-4% -$20.3M 0.17% 114
2015
Q3
$449M Sell
964,372
-26,046
-3% -$14M 0.15% 132
2015
Q2
$505M Buy
990,418
+64,211
+7% +$31.3M 0.15% 134
2015
Q1
$418M Sell
926,207
-25,358
-3% -$10.7M 0.13% 165
2014
Q4
$390M Sell
951,565
-9,573
-1% -$3.76M 0.12% 174
2014
Q3
$347M Sell
961,138
-58,548
-6% -$19.6M 0.11% 177
2014
Q2
$288M Sell
1,019,686
-43,055
-4% -$12.8M 0.09% 215
2014
Q1
$319M Buy
1,062,741
+17,417
+2% +$5.37M 0.1% 192
2013
Q4
$288M Buy
1,045,324
+40,607
+4% +$11.7M 0.09% 209
2013
Q3
$314M Sell
1,004,717
-10,501
-1% -$2.76M 0.11% 180
2013
Q2
$228M Buy
+1,015,218
New +$236M 0.08% 235

Other funds holding REGN

Northern Trust's REGN Position: Q1 2026 in Review

Northern Trust reduced its Regeneron Pharmaceuticals (REGN) stake by 0.32% in Q1 2026, selling an estimated $2.29M and leaving 941,941 shares worth $728M. The position accounts for 0.1% of the portfolio, ranked #192.

Northern Trust first reported a position in REGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.02B in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Northern Trust held 941,941 shares of Regeneron Pharmaceuticals worth $728M as of Q1 2026.
  • Northern Trust sold 2,992 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $2.29M.
  • Regeneron Pharmaceuticals made up 0.1% of Northern Trust's portfolio in Q1 2026, its #192 holding.
  • Northern Trust first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Northern Trust's Regeneron Pharmaceuticals position peaked at $1.02B in Q2 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.